DVDina Vojinovic

Dina Vojinovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dina Vojinovic has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Temporal Trends in Janus Kinase Inhibitor ( JAKi ) Use Across Five European Countries: A DARWIN EU Network Study

    by Xihang Chen, Andrei Barbulescu, George Corby, Saeed Hayati, Annika Jodicke, Toni Lehtonen, Hedvig Marie Egeland Nordeng, Alexandra Pacurariu, Gabriel Sanfélix‐Gimeno, Nhung T. H. Trinh, et al.

    Introduction: Janus kinase inhibitors (JAKi) are increasingly used for autoimmune conditions despite existing safety concerns. This study aims to estimate the incidence of new JAKi use over time and characterise users in Europe to support future safety studies. Methods: The study included individuals from five European data sources within the DARWIN EU network: FinOMOP‐HILMO (Finland; primary and secondary care), IPCI (the Netherlands; primary), IQVIA DA Germany (Germany; primary), NLHR (Norway; primary and secondary), VID (Spain; primary and secondary) from 1 January 2017. Annual incidence of JAKi (abrocitinib, baricitinib, filgotinib, tofacitinib, upadacitinib) was up to 31 December 2023. Patient characteristics and treatment duration were described. Results: Incidence of JAKi use increased over time, with transient declines during the COVID‐19 pandemic. Initiators, except for abrocitinib, were predominantly aged 41–60 years. Rheumatoid arthritis was the most common indicated condition, except for abrocitinib, for which atopic dermatitis predominated. Median treatment duration was generally less than 1 year. Tofacitinib and baricitinib had the lowest proportions of prior JAKi use, whereas up to 17% and 16% of upadacitinib and filgotinib initiators had received prior treatment with another JAKi. Findings were consistent across data sources, although incidence rates varied according to the healthcare sector captured. Conclusions: Incidence of JAKi use generally increased, with tofacitinib being the most initiated JAKi. Treatment durations were relatively short and switching between JAKi was common. The current study provides an overview of indication distribution and characterises JAKi treatment, while offering a framework for future research.

  • Open Access

    Integrative cross-omics analysis identifies DNA methylation signatures associated with bilateral hippocampal volume, asymmetry and atrophy rate in the general population

    by Dan Liu, Valentina Talevi, Juliana F. Tavares, Ruiqi Wang, Mohammed A Imtiaz, Konstantinos Melas, Alexander Teumer, Katharina Wittfeld, Robert F Hillary, Dina Vojinovic, et al.

    The hippocampus exhibits volumetric differences between the left and right hemispheres (LHCV and RHCV) and asymmetry, yet the molecular mechanisms underlying these features remain unclear. In this study, we performed a meta-analysis of epigenome-wide association studies (EWAS) across six population-based cohorts (n=8,156; 53% women; mean age: 60.7 years) to identify blood-based methylation signatures associated with LHCV, RHCV, and hippocampal asymmetry. Integrative cross-omics analyses using individual-level genetic, methylation, and gene expression data (n > 2,624 participants from the Rhineland Study) revealed 15 CpG/DMR-gene expression pairs linked to LHCV and 18 pairs to RHCV, implicating pathways involved in neuronal differentiation and immune processes. Notably, baseline methylation at these loci predicted bilateral hippocampal atrophy rates, explaining over 10% of the variation. Four CpGs were consistently associated with hippocampal asymmetry cross-sectionally and longitudinally, exhibiting sex-specific differences. Additionally, adherence to healthy dietary patterns was associated with these methylation signatures, highlighting modifiable influences on hippocampal health and atrophy.

  • Open Access

    Unraveling interindividual variation of trimethylamine N‐oxide and its precursors at the population level

    by Sergio Andreu‐Sánchez, Shahzad Ahmad, Alexander Kurilshikov, Marian Beekman, Mohsen Ghanbari, Martijn van Faassen, Inge C. L. van Den Munckhof, Marinka Steur, Amy Harms, Thomas Hankemeier, et al.

    Trimethylamine N‐oxide (TMAO) is a circulating microbiome‐derived metabolite implicated in the development of atherosclerosis and cardiovascular disease (CVD). We investigated whether plasma levels of TMAO, its precursors (betaine, carnitine, deoxycarnitine, choline), and TMAO‐to‐precursor ratios are associated with clinical outcomes, including CVD and mortality. This was followed by an in‐depth analysis of their genetic, gut microbial, and dietary determinants. The analyses were conducted in five Dutch prospective cohort studies including 7834 individuals. To further investigate association results, Mendelian Randomization (MR) was also explored. We found only plasma choline levels (hazard ratio [HR] 1.17, [95% CI 1.07; 1.28]) and not TMAO to be associated with CVD risk. Our association analyses uncovered 10 genome‐wide significant loci, including novel genomic regions for betaine (6p21.1, 6q25.3), choline (2q34, 5q31.1), and deoxycarnitine (10q21.2, 11p14.2) comprising several metabolic gene associations, for example, CPS1 or PEMT. Furthermore, our analyses uncovered 68 gut microbiota associations, mainly related to TMAO‐to‐precursors ratios and the Ruminococcaceae family, and 16 associations of food groups and metabolites including fish‐TMAO, meat‐carnitine, and plant‐based food‐betaine associations. No significant association was identified by the MR approach. Our analyses provide novel insights into the TMAO pathway, its determinants, and pathophysiological impact on the general population.


  • Open Access

    Epigenetic and Metabolomic Biomarkers for Biological Age: A Comparative Analysis of Mortality and Frailty Risk

    by Lieke M Kuiper, Harmke A Polinder-Bos, Daniele Bizzarri, Dina Vojinovic, Costanza L Vallerga, Marian Beekman, Martijn E T Dollé, Mohsen Ghanbari, Trudy Voortman, Marcel J T Reinders, et al.

    Biological age captures a person’s age-related risk of unfavorable outcomes using biophysiological information. Multivariate biological age measures include frailty scores and molecular biomarkers. These measures are often studied in isolation, but here we present a large-scale study comparing them. In 2 prospective cohorts (n = 3 222), we compared epigenetic (DNAm Horvath, DNAm Hannum, DNAm Lin, DNAm epiTOC, DNAm PhenoAge, DNAm DunedinPoAm, DNAm GrimAge, and DNAm Zhang) and metabolomic-based (MetaboAge and MetaboHealth) biomarkers in reflection of biological age, as represented by 5 frailty measures and overall mortality. Biomarkers trained on outcomes with biophysiological and/or mortality information outperformed age-trained biomarkers in frailty reflection and mortality prediction. DNAm GrimAge and MetaboHealth, trained on mortality, showed the strongest association with these outcomes. The associations of DNAm GrimAge and MetaboHealth with frailty and mortality were independent of each other and of the frailty score mimicking clinical geriatric assessment. Epigenetic, metabolomic, and clinical biological age markers seem to capture different aspects of aging. These findings suggest that mortality-trained molecular markers may provide novel phenotype reflecting biological age and strengthen current clinical geriatric health and well-being assessment.


  • Open Access

    Evaluation of epigenetic and metabolomic biomarkers indicating biological age

    by Lieke M. Kuiper, Harmke A. Polinder-Bos, Daniele Bizzarri, Dina Vojinovic, Costanza L. Vallerga, Marian Beekman, Martijn E.T. Dollé, Mohsen Ghanbari, Trudy Voortman, Marcel J.T. Reinders, et al.

    Biological age captures a person’s age-related risk of unfavorable outcomes using biophysiological information. Multivariate biological age measures include frailty scores and molecular biomarkers. These measures are often studied in isolation, but here we present a large-scale study comparing them. In two prospective cohorts ( n =3,196), we compared epigenetic (DNAm Horvath, DNAm Hannum, DNAm PhenoAge, DNAm GrimAge) and metabolomic-based (MetaboAge, MetaboHealth) biomarkers in reflection of biological age, as represented by five frailty measures and overall mortality. We observed that mortality-trained biological age markers, DNAm GrimAge and MetaboHealth, outperformed age-trained biomarkers in frailty reflection and mortality prediction. The associations of DNAm GrimAge and MetaboHealth with frailty and mortality were independent of each other and of the frailty score mimicking clinical geriatric assessment. Epigenetic, metabolomic, and clinical biological age markers seem to capture different aspects of aging. These findings suggest that mortality-trained molecular markers may provide novel phenotype reflecting biological age and strengthen current clinical geriatric health and well-being assessment.


  • Open Access

    TMAO and its precursors in relation to host genetics, gut microbial composition, diet, and clinical outcomes: Meta-analysis of 5 prospective population-based cohorts

    by Sergio Andreu-Sánchez, Shahzad Ahmad, Alexander Kurilshikov, Marian Beekman, Mohsen Ghanbari, Martijn van Faassen, Inge C.L. van Den Munckhof, Marinka Steur, Amy Harms, Thomas Hankemeier, et al.

    Trimethylamine N-oxide (TMAO) is a circulating microbiome-derived metabolite implicated in the development of atherosclerosis and cardiovascular disease (CVD). We investigated whether plasma levels of TMAO, its precursors (betaine, carnitine, deoxycarnitine, choline) and TMAO-to-precursor ratios associate with clinical outcomes, including CVD and mortality. This was followed by an in-depth analysis of their genetic, gut microbial and dietary determinants. The analyses were conducted in five Dutch prospective cohort studies including 7,834 individuals. To further investigate association results, Mendelian Randomization (MR) was also explored. We found only plasma choline levels (hazard ratio (HR) 1.17, (95% CI 1.07; 1.28)) and not TMAO to be associated with CVD risk. Our association analyses uncovered 10 genome-wide significant loci, including novel genomic regions for betaine (6p21.1, 6q25.3), choline (2q34, 5q31.1) and deoxycarnitine (10q21.2, 11p14.2) comprising several metabolic gene associations, e.g., CPS1 or PEMT . Furthermore, our analyses uncovered 68 gut microbiota associations, mainly related to TMAO-to-precursors ratios and the Oscillospiraceae family and 16 associations of food groups and metabolites including fish-TMAO, meat-carnitine and plant-based food-betaine associations. No significant association was identified by MR approach. Our analyses provide novel insights into the TMAO pathway, its determinants and pathophysiological impact in the general population.


  • Open Access

    Relationship between gut microbiota and circulating metabolites in population-based cohorts

    by Dina Vojinovic, Djawad Radjabzadeh, Alexander Kurilshikov, Najaf Amin, Cisca Wijmenga, Lude Franke, M. Arfan Ikram, Andre G. Uitterlinden, Alexandra Zhernakova, Jingyuan Fu, et al.

    Gut microbiota has been implicated in major diseases affecting the human population and has also been linked to triglycerides and high-density lipoprotein levels in the circulation. Recent development in metabolomics allows classifying the lipoprotein particles into more details. Here, we examine the impact of gut microbiota on circulating metabolites measured by Nuclear Magnetic Resonance technology in 2309 individuals from the Rotterdam Study and the LifeLines-DEEP cohort. We assess the relationship between gut microbiota and metabolites by linear regression analysis while adjusting for age, sex, body-mass index, technical covariates, medication use, and multiple testing. We report an association of 32 microbial families and genera with very-low-density and high-density subfractions, serum lipid measures, glycolysis-related metabolites, ketone bodies, amino acids, and acute-phase reaction markers. These observations provide insights into the role of microbiota in host metabolism and support the potential of gut microbiota as a target for therapeutic and preventive interventions.


  • Open Access

    Common genetic variation indicates separate etiologies for periventricular and deep white matter hyperintensities

    by Nicola J Armstrong, Karen A Mather, Muralidharan Sargurupremraj, Maria J Knol, Rainer Malik, Claudia L Satizabal, Lisa R Yanek, Wen Wei, Vilmundur Gudnason, Nicole D Deuker, et al.

    We conducted a genome-wide association meta-analysis of two ischemic white matter disease subtypes in the brain, periventricular and deep white matter hyperintensities (PVWMH and DWMH). In 26,654 participants, we found 10 independent genome-wide significant loci only associated with PVWMH, four of which have not been described previously for total WMH burden (16q24.2, 17q21.31, 10q23.1, 7q36.1). Additionally, in both PVWMH and DWMH we observed the previous association of the 17q25.1 locus with total WMH. We found that both phenotypes have shared but also distinct genetic architectures, consistent with both different underlying and related pathophysiology. PVWMH had more extensive genetic overlap with small vessel ischemic stroke, and unique associations with several loci implicated in ischemic stroke. DWMH were characterized by associations with loci previously implicated in vascular as well as astrocytic and neuronal function. Our study confirms the utility of these phenotypes and identifies new candidate genes associated only with PVWMH.


  • A multi-ancestry genome-wide study incorporating gene–smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure

    by Yun Ju Sung, Lisa de Las Fuentes, Thomas W Winkler, Daniel I Chasman, Amy R Bentley, Aldi T Kraja, Ioanna Ntalla, Helen R Warren, Xiuqing Guo, Karen Schwander, et al.

    Elevated blood pressure (BP), a leading cause of global morbidity and mortality, is influenced by both genetic and lifestyle factors. Cigarette smoking is one such lifestyle factor. Across five ancestries, we performed a genome-wide gene–smoking interaction study of mean arterial pressure (MAP) and pulse pressure (PP) in 129 913 individuals in stage 1 and follow-up analysis in 480 178 additional individuals in stage 2. We report here 136 loci significantly associated with MAP and/or PP. Of these, 61 were previously published through main-effect analysis of BP traits, 37 were recently reported by us for systolic BP and/or diastolic BP through gene–smoking interaction analysis and 38 were newly identified (P < 5 × 10−8, false discovery rate < 0.05). We also identified nine new signals near known loci. Of the 136 loci, 8 showed significant interaction with smoking status. They include CSMD1 previously reported for insulin resistance and BP in the spontaneously hypertensive rats. Many of the 38 new loci show biologic plausibility for a role in BP regulation. SLC26A7 encodes a chloride/bicarbonate exchanger expressed in the renal outer medullary collecting duct. AVPR1A is widely expressed, including in vascular smooth muscle cells, kidney, myocardium and brain. FHAD1 is a long non-coding RNA overexpressed in heart failure. TMEM51 was associated with contractile function in cardiomyocytes. CASP9 plays a central role in cardiomyocyte apoptosis. Identified only in African ancestry were 30 novel loci. Our findings highlight the value of multi-ancestry investigations, particularly in studies of interaction with lifestyle factors, where genomic and lifestyle differences may contribute to novel findings.


  • Open Access

    Multi-ancestry genome-wide gene–smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids

    by COGENT-Kidney Consortium, Amy R. Bentley, EPIC-InterAct Consortium, Understanding Society Scientific Group, Lifelines Cohort, Yun J. Sung, Michael R. Brown, Thomas W. Winkler, Aldi T. Kraja, Ioanna Ntalla, et al.

    The concentrations of high- and low-density-lipoprotein cholesterol and triglycerides are influenced by smoking, but it is unknown whether genetic associations with lipids may be modified by smoking. We conducted a multi-ancestry genome-wide gene–smoking interaction study in 133,805 individuals with follow-up in an additional 253,467 individuals. Combined meta-analyses identified 13 new loci associated with lipids, some of which were detected only because association differed by smoking status. Additionally, we demonstrate the importance of including diverse populations, particularly in studies of interactions with lifestyle factors, where genomic and lifestyle differences by ancestry may contribute to novel findings.